EULAT Eradicate GBC

Summary

Gallstones are relatively frequent in women and constitute one of the main risk factors for gallbladder cancer (GBC).

Currently, GBC diagnosis is mainly based on imaging (ultrasound or abdominal CT) associated with invasive examinations (biopsy and surgery), with no marker available to date to accurately predict risk and diagnose the disease early. The only curative treatment for GBC remains surgery with complete resection of tumors in early stages.

Given the aggressiveness of GBC and the very limited therapeutic options, as well as the possibility of preventing GBC by cholecystectomy during the 10 to 20 years required for the development of gallbladder tumors, it is imperative to develop effective and efficient prevention strategies based on a prioritization of interventions according to environmental and genetic-molecular risk factors.

The investigators aim to identify epidemiological factors linked to the development of GBC, and to identify, validate and functionally characterize genetic-molecular markers in blood, saliva, urine, bile and stool that allow risk prediction, early diagnosis and precision treatment of incidental tumors.

Conditions

• Gallbladder Cancer
• Gallstone Disease

Interventions

OTHER

None, observational study.

Epidemiological, clinical and dietary data will be collected along with blood, saliva, urine, bile, feces and gallbladder tissue samples.

Sponsors & Collaborators

• Heidelberg University Hospital (UKHD, Germany, Coordinator)

  collaborator UNKNOWN

• Universidad Austral de Chile (UACH, Chile)

  collaborator UNKNOWN

• Universidad de la Frontera (UFRO, Chile)

  collaborator UNKNOWN

• Universidad Católica del Maule (UCM, Chile)

  collaborator UNKNOWN

• Centre international de recherche sur le cancer (IARC, France)

  collaborator UNKNOWN

• Universidad de Chile (UChile, Chile)

  collaborator UNKNOWN

• Instituto Nacional de Enfermedades Neoplásicas (INEN, Peru)

  collaborator UNKNOWN

• Universidad Mayor de San Simón (UMSS, Bolivia)

  collaborator UNKNOWN

• Oslo University Hospital

  collaborator OTHER

• Sanatorio el Carmen (Argentina)

  collaborator UNKNOWN

• Pontificia Universidad Católica de Chile (PUC, Chile)

  collaborator UNKNOWN

• University of Bristol

  collaborator OTHER

• University of Oslo

  collaborator OTHER

• Chilean institutions (See detailed study description below)

  collaborator UNKNOWN

• Peruvian institutions (See detailed study description below)

  collaborator UNKNOWN

• Bolivian institutions (See detailed study description below)

  collaborator UNKNOWN

• Argentinian institutions (See detailed study description below)

  collaborator UNKNOWN

• Centre Paul Strauss

  lead OTHER

Principal Investigators

• Justo LORENZO BERMEJO, PhD · Heidelberg University Hospital (UKHD, Germany) and Centre Paul Strauss (CPS, France)

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-12-01

Primary Completion

2028-12-31

Completion

2028-12-31

Countries

• Argentina
• Bolivia
• Chile
• France
• Peru

Study Locations